Skip to content
topics.

Pancreatic cancer mRNA vaccine shows durable responses in early trial

scienceApr 19, 202630615

A personalized mRNA vaccine tailored to each patient’s tumor mutations produced durable responses in a small phase I trial for pancreatic cancer. Nearly all patients who responded to the vaccine remained alive six years after treatment. The study was early-stage and small, and researchers say larger randomized trials are required to determine whether the vaccine can improve survival for more patients.

Key Highlights

Personalized mRNA vaccine matched to patients' tumor mutations in phase I trial
Nearly all responders remained alive six years after treatment
Larger randomized trials are needed to confirm survival benefit
1 source
nbcnews.comPancreatic cancer mRNA vaccine shows lasting results in an early trial

Related

Artemis II commander shares far-side 'Earthset' iPhone videosciencePancreatic cancer mRNA vaccine shows durable responses in early trialscienceArtemis II astronaut Christina Koch posts video of balance issues after returnscienceBlue Origin's New Glenn puts BlueBird 7 in wrong orbit after upper‑stage glitchscience